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Abstract
Background: The accurate normalization of differentially expressed genes in lung cancer is
essential for the identification of novel therapeutic targets and biomarkers by real time RT-PCR
and microarrays. Although classical "housekeeping" genes, such as GAPDH, HPRT1, and beta-actin
have been widely used in the past, their accuracy as reference genes for lung tissues has not been
proven.
Results: We have conducted a thorough analysis of a panel of 16 candidate reference genes for
lung specimens and lung cell lines. Gene expression was measured by quantitative real time RT-
PCR and expression stability was analyzed with the softwares GeNorm and NormFinder, mean of
|ΔCt| (= |Ct Normal-Ct tumor|) ± SEM, and correlation coefficients among genes. Systematic
comparison between candidates led us to the identification of a subset of suitable reference genes
for clinical samples: IPO8, ACTB, POLR2A, 18S, and PPIA. Further analysis showed that IPO8 had
a very low mean of |ΔCt| (0.70 ± 0.09), with no statistically significant differences between normal
and malignant samples and with excellent expression stability.
Conclusion: Our data show that IPO8 is the most accurate reference gene for clinical lung
specimens. In addition, we demonstrate that the commonly used genes GAPDH and HPRT1 are
inappropriate to normalize data derived from lung biopsies, although they are suitable as reference
genes for lung cell lines. We thus propose IPO8 as a novel reference gene for lung cancer samples.
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Lung cancer is one of the most fatal types of cancer in the
world. The overall 5-yr survival rate remains at 15%, as
most patients present with advanced disease [1]. The
prognosis for the patients is highly correlated to the stage
of disease at the time of diagnosis. Lung cancer is usually
diagnosed in an advanced stage, which is frequently too
late for surgical intervention, and therefore, it usually
becomes incurable.
During the past few years, the application of microarray
technology has revolutionized cancer genomics, making
possible the simultaneous evaluation of the expression of
thousands of genes. Newly discovered gene signatures in
lung [2] and breast cancer [3] may predict disease out-
come and contribute to the design of novel therapeutic
targets. The use of gene expression profiles in routine clin-
ical practice is highly dependent on precise identification
and robust validation of these gene signatures, which
relies upon a high-throughput RT-PCR-based technology
is available.
Quantitative real time PCR (qRT-PCR) is one of the most
powerful quantification methods for gene expression
analysis. This technology has been applied to identify
molecular tumor biomarkers [4], splice variants of target
genes [5], and microRNAs [6], and to quantify circulating
DNA [7], with the final goal of improving diagnosis and
predicting clinical outcome [8]. In these studies, target
gene expression is usually quantified in relation to a stably
expressed reference gene, simultaneously determined in
the sample [9]. Although it is assumed that these reference
genes are constitutively expressed in certain tissues and
under certain circumstances, the literature shows that the
expression levels of some of the "classic" endogenous con-
trol genes may in fact vary in different tissues, cell types,
and disease stages [10]. It is then clear that if US Food and
Drug Administration (FDA) or other Regulatory Agencies
are to approve any diagnostic or prognostic test based on
qRT-PCR, the proof of the stability of the proposed refer-
ence genes will be a major requirement. Therefore, the
selection of suitable reference genes is a key prerequisite to
control the variability of clinical samples.
Recent lung cancer molecular profiling studies have
employed a group of widely used endogenous control
genes, such as GAPDH [11], beta-actin (ACTB) [12],
TATA-binding protein (TBP) [4], 18s-rRNA [13], HMBS
[5] and phenylalanine hydroxylase [14], for RT-PCR. Such
genes were selected in the past as reference genes for non-
or semi-quantitative techniques and have been used for
many years in most experiments to measure qualitative
gene expression changes. These widely used reference
genes were not selected for specific tissue types or organs
and were mainly validated in cell lines. The advent of qRT-
PCR allows for the accurate quantification of expression
changes, albeit some studies have continued using these
old reference genes without a re-evaluation of their suita-
bility as endogenous control genes. The requirement for a
specific validation of the currently used reference genes is
compelling and the need for robust stable endogenous
genes for lung cancer is urgent.
We studied a panel of sixteen genes (some of them fre-
quently used as endogenous controls) and analyzed their
suitability as reference genes in both lung cell lines and
clinical lung samples. From those, we identified Importin
8 (IPO8) as the most suitable gene for normalizing clini-
cal lung specimens.
Methods
Tumor tissues and cultured cells
Tumor samples were obtained from Non-Small Cell Lung
Cancer (NSCLC) patients who underwent tumor resec-
tional surgery at the University Hospital of Navarra (Pam-
plona, Spain) and at the Hospital Marqués de Valdecilla
(Santander, Spain), under approved ethical protocols and
informed consent from each patient (See Supplemental
Table 1, Additional file 1). Surgically removed samples
(the tumor and its corresponding matched normal tissue)
were snap-frozen in liquid nitrogen. A 5 μm section was
cut with a cryostat, and analyzed by histology. The general
strategy of our analysis is illustrated in Figure 1. In a first
study, consisting in the analysis of GAPDH and HPRT1
mRNA quantification by qRT-PCR analysis, samples from
the Set A of patients were used (Set A). A second analysis
was conducted with the Human Endogenous Control
Plate (#4367563, Applied Biosystems) using the Set B of
samples. A third analysis included the clinical validation
of the selected optimally performing reference genes and
was carried out on Sets A+C primary tumor samples and
their paired non-malignant lung tissues.
Non-malignant human bronchial epithelial (NHBE) and
small airways epithelial cells (SAEC), and seven NSCLC
cell lines (NCI-H460, NCI-H1385, NCI-H157, NCI-
H1648, NCI-H23, NCI-H441 and SK-MES-1) were used.
Non-tumor cells were obtained from CAMBREX (NJ,
USA), and tumor cells were obtained from ATCC (VA,
USA). Non-malignant cells were grown in Bronchial Epi-
thelial Cell Basal Medium (CAMBREX, NJ, USA), and
NSCLC cell lines in RPMI-1640 supplemented with 10%
fetal calf serum (Invitrogen, Carlsbad, CA).
RNA extraction and qRT-PCR
Total RNA was isolated using the AllPrep DNA/RNA mini
Kit (Qiagen, CA, USA) as described by the manufacturer.
RNA concentrations and the A260/A280 ratio were meas-
ured with a NanoDrop® ND-1000 (NanoDrop Technolo-
gies, Montchanin, DE, USA). The threshold inclusionPage 2 of 11
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ratio. The absence of contaminating DNA was analyzed by
running the samples through 2% agarose gels. RNA qual-
ity was also determined in a Bioanalyzer platform (Agi-
lent, CA, USA). Two micrograms RNA were reverse
transcribed. Before transcription, RNA was denatured for
5 min at 65°C followed by cooling on ice. First strand
cDNA synthesis was carried out with SuperScript™ III
Reverse Transcriptase (Invitrogen) and random primers
(Invitrogen) in a total volume of 20 μl. Reverse transcrip-
tion was performed at 42°C for 1 h followed by 72°C for
15 min. Finally, RNase H was added to the reaction mix-
ture for 20 min at 37°C. cDNA was stored at -80°C until
RT-PCR analysis. Each RNA sample was controlled for
genomic DNA contamination by a reaction mix without
reverse transcriptase addition. All cDNAs were diluted
1:10 before being used as PCR template.
Schematic diagram of the overall procedure for the identification of accurate reference genesFigure 1
Schematic diagram of the overall procedure for the identification of accurate reference genes. General strategy 
to identify the most accurate reference genes for lung cancer mRNA quantification analysis in three different sets of samples.Page 3 of 11
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performed with the TaqMan® Low Density Human Endog-
enous Control Panel (Applied Biosystems), according to the
manufacturer's protocol. This plate contains sixteen
human endogenous candidate genes (Table 1). qRT-PCR
was performed with an Applied Biosystems 7900HT Fast
Real-time PCR System. PCR efficiencies were calculated
according to Rasmussen [15] and the standard curves gen-
erated in the qRT- PCR were plotted as Ct values versus
logarithms of the given concentrations of the DNA tem-
plates.
Determination of gene stability
To evaluate suitability of candidates as reference genes, we
applied two powerful previously published Microsoft
Excel-based applications: 1) GeNorm [16], which calcu-
lates gene stability as the standard deviation (SD) of the
log2-transformed expression ratios of each reference gene.
The program is available on the Internet http://
medgen.ugent.be/genorm/. Ct values were converted into
relative quantities for analysis with GeNorm, considering
the PCR efficiencies of the genes. 2) NormFinder [17],
that uses a model-based approach to estimate expression
stability based on intra- and intergroup variations for can-
didate endogenous control genes. It is also freely available
on the Internet http://www.mdl.dk.
Analysis of the absolute variation of Ct values
Ct variations were expressed as ΔCt, the difference
between Ct Normal and Ct Tumor (ΔCt = Ct Normal-Ct
Tumor). To analyze the absolute variation of Ct values, we
calculated the mean and the standard error of the mean
(SEM) of absolute values of ΔCt ("|ΔCt|") for each gene.
Microarray data analysis
Three lung cancer patient microarrays (HuGene-FL, HG-
U95A, HG-U133A), previously described [18-20], were
analyzed. The raw datasets are publicly available at: http:/
/www.affymetrix.com/products/arrays/index.affx. For
analysis, significant differences in a specific reference gene
candidate expression, between normal and tumor sam-
ples from patients (lung adenocarcinomas and squamous
cell lung carcinomas) were identified by ANOVA. p-values
< 0.05 were considered statistically significant.
Statistical analysis
All statistical evaluations were carried out using the SPSS
software package. Correlations between genes were deter-
mined by Pearson's test. All p-values < 0.01 were consid-
ered statistically significant in this analysis.
Normal distributions were assessed with the Shapiro-
Wilk's W test. Differences in gene expressions between
nonmalignant and malignant samples were calculated by
the Student's t test for paired data with normal distribu-
tion, or by Wilcoxon's test for paired data following non-
parametric distribution. p-values were considered signifi-
cant when p < 0.05.
Results
HPRT1 and GAPDH, two genes commonly used for 
normalization, are inappropriate reference genes for 
human lung tissue analyses
GAPDH and HPRT1 have been recommended as suitable
reference genes for lung cancer research [21]. Thus, we
first evaluated expression levels of these genes in the Set A
samples. The analysis revealed that gene mRNA levels
were significantly higher in tumors than in non-malig-
Table 1: Genes included in the TaqMan® low density human endogenous control panel
Gene symbol Gene name Function
18S 18S Ribosomal RNA One 18S molecule makes the small subunit of the ribosome
ACTB Beta-Actin Cytoskeletal structural protein
B2M Beta-2-Microglobulin Beta-chain of major histocompatibility complex class I molecules
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Oxidoreductase in glycolysis and gluconeogenesis
GUSB Beta-Glucuronidase Degradation of dermatan and keratan sulfates
HMBS Hydroxymethylbilane synthase Heme synthesis, porphyrin metabolism
HPRT1 Hypoxanthine phosphoribosyl transferase Purine synthesis in salvage pathway
IPO8 Importin8 Function in nuclear protein import
PGK1 Phosphoglycerate kinase Glycolytic enzyme
POLR2A RNA Polymerase II Catalyzes the RNA synthesis from DNA
PPIA Peptidylprolyl isomerase A Catalyzes the cis-trans isomerization of proline imidic peptide bonds in 
oligopeptides, accelerating folding
RPLP0 Ribosomal large P0 Ribosome biogenesis and assembly
TBP TATA binding protein General RNA polymerase II transcription factor
TFRC Transferrin receptor Cellular uptake of iron
UBC Ubiquitin C Protein degradation
YWHAZ Tyrosinmonooxygenase/Tryp-tophanmonooxygenase 
activation protein
Signal transduction by binding to phosphorylated serine residues on a 
variety of signaling moleculesPage 4 of 11
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HPRT1 (p = 0.00003). Ct variations (ΔCt = Ct Normal-Ct
Tumor) were calculated for each gene (Supplemental
Table 2, Additional file 1). Ideally, a good reference gene
should have |ΔCt| values close to zero with low SEM.
However, as shown in Figure 2, neither GAPDH (|ΔCt| =
2.27 ± 0.31) nor HPRT1 (|ΔCt| = 1.81 ± 0.26) showed this
pattern.
We also performed a statistical analysis of three lung can-
cer microarrays previously published [18-20]. The
ANOVA analysis (p < 0.05) confirmed that there was a sig-
nificant increase in both GAPDH and HPRT1 expression
levels in tumor samples compared to normal tissues (Sup-
plemental Table 3, Additional file 1). In summary, in lung
clinical samples, as described in several other cancers [22-
25], the expression of the two most commonly used refer-
ence genes is heterogeneous and, consequently, not valid
for gene expression normalization.
Variable expression of sixteen endogenous control genes in 
both lung cell lines and clinical samples
In the next experiments, we used the Low Density Endog-
enous Control Panel on human samples and cultured cells,
with the goal of identifying suitable genes for normaliza-
tion. We first analyzed the efficiency of the PCR assay. The
linear correlation coefficient (R2) of the standard curves of
all the genes ranged from 0.9942 to 0.999. Based on the
slopes of the standard curves, the amplification efficien-
cies of the standards were from 91% to 100%, which were
derived from the formula E = (101/-slope -1) × 100 [15]. The
Ct values of the 16 genes in all the samples were within
10.7 and 35.3 cycles.
Differential expression levels and dispersion of individual
Ct values from the mean Ct value were calculated for the
16 genes (Table 2). Except for 18S, which was the gene
with the highest expression, all the other candidates
showed Cts ranging from 19 to 33. In NSCLC cell lines,
non-malignant cells, and lung tumors, the gene with the
Variations of GAPDH and HPRT1 expression levelsFigure 2
Variations of GAPDH and HPRT1 expression levels. Mean ± SEM of absolute values of ΔCt (|ΔCt| = |Ct Normal-Ct 
Tumor|) of the two commonly used reference genes (GAPDH and HPRT1) in paired lung clinical samples (Set A).Page 5 of 11
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highest expression was ACTB. However, in normal clinical
samples, HMBS showed the lowest level of expression (Ct
= 32.68 ± 0.76), and B2M was highest expressed transcript
(Ct = 22.94 ± 0.75) (Table 2).
The SD of Ct values for each control gene was also calcu-
lated in the samples (Table 2). For NSCLC cell lines, B2M
(SD = 0.51) expression showed the lowest SD. On the
contrary, in non-malignant cells, GAPDH (SD = 0.00) was
the gene with the lowest variability. B2M had the lowest
SD for both tumor and normal clinical samples (1.18 and
0.75, respectively).
Because of the different patterns of expression of cultured
cells and clinical samples, we decided to conduct further
analyses separately. In the search for the most stable refer-
ence candidates, the gene expression stability was ana-
lyzed with GeNorm and NormFinder softwares.
In lung cell lines, five genes (including GAPDH and HPRT1) 
perform optimally as endogenous control genes
As explained in Materials and Methods, GeNorm and
NormFinder are two mathematical tools recently devel-
oped to identify expression stability of a set of candidate
genes. The model-based approach (NormFinder) selects
the candidates with minimal combined inter- and intra-
group expression variation. The pairwise comparison
approach (GeNorm) selects genes with a low intra-group
variation and roughly the same no vanishing intergroup
variation. GeNorm calculates the gene expression stability
measure "M" of one gene, based on the average pairwise
variation between all studied genes. The lowest M values
characterize genes with the most stable expression.
Expression stabilities were first evaluated with GeNorm in
cell lines (Table 3). In the ranking of expression stability,
these genes were top-classified (M < 0.5): PPIA and
RPLPO>GAPDH>18S>HPRT1. Genes with middle stabil-
ity (0.5 <M < 0.7) were
GUSB>POLR2A>HMBS>PGK1>UBC>ACTB. The less sta-
ble genes were B2M, TFRC, YWHAZ, IPO8 and TBP,
whose M values were higher than 0.7 (Table 3).
Using NormFinder with arbitrary cut-off values of 0.4 and
0.6 in the cell lines, the most stable genes were
PPIA>RPLPO>HPRT1>GAPDH>18S>GUSB (Table 3).
Genes with intermediate stability included
POLR2A>UBC>PGK1>HBMS>ACTB>B2M>TFRC.
Finally, YWHAZ, IPO8, and TBP were the least stable
genes. Considering results from both softwares, PPIA,
RPLPO, GAPDH, HPRT1, and 18S can be considered accu-
rate reference genes in lung cancer cell lines.
We further determined correlations between genes by
Pearson's test, considering statistically significant p-values
< 0.01 (supplemental Text S1 and supplemental Table 4,
Additional file 1). Interestingly, our five candidate genes
(PPIA, RPLPO, GAPDH, HPRT1, and 18S) exhibited a
very strong correlation among themselves (r = 0.949–
0.814).
Determination of a set of five candidate genes to be used 
as reference genes in clinical samples
In clinical samples, GeNorm identified the following genes
with M values < 0.5 (very stable): IPO8,
ACTB>POLR2A>18S; genes with M values ranging from
0.5 to 0.7 included PPIA>HMBS>RPLPO>YWHAZ. The
group with M values >0.7 (not suitable for normalization)
were
Table 2: Comparison of mean cycle threshold (Ct ± SD) values across different sample groups
Cultured cells Clinical samples
Tumor Normal Tumor Normal
18S 12.88 ± 0.61 11.24 ± 0.73 12.60 ± 1.62 13.79 ± 1.00
ACTB 22.20 ± 1.07 19.30 ± 0.26 23.07 ± 1.36 23.59 ± 1.15
B2M 24.99 ± 0.51 23.46 ± 0.43 23.21 ± 1.18 22.94 ± 0.75
GAPDH 22.61 ± 0.72 20.64 ± 0.00 24.48 ± 1.92 27.13 ± 1.11
GUSB 29.36 ± 0.73 28.61 ± 0.36 28.81 ± 1.36 29.77 ± 1.04
HMBS 29.23 ± 1.11 28.41 ± 0.45 30.89 ± 1.47 32.68 ± 0.76
HPRT1 27.07 ± 0.71 26.20 ± 0.40 29.10 ± 1.90 30,63 ± 0.97
IPO8 29.65 ± 1.19 28.97 ± 0.03 30.43 ± 1.37 30.91 ± 0.97
PGK1 24.97 ± 0.83 23.15 ± 0.32 25.23 ± 1.63 27.56 ± 0.92
POLR2A 27.95 ± 0.93 26.37 ± 0.06 28.55 ± 1.32 29.58 ± 1.06
PPIA 23.16 ± 0.82 21.49 ± 0.23 24.37 ± 1.47 26.00 ± 1.07
RPLP0 23.01 ± 0.71 21.02 ± 0.37 24.34 ± 1.82 26.01 ± 0.98
TBP 30.95 ± 1.75 29.00 ± 0.96 31.79 ± 2.12 32.59 ± 1.16
TFRC 26.71 ± 0.76 26.64 ± 0.13 27.94 ± 2.18 28.65 ± 1.06
UBC 23.11 ± 0.62 20.83 ± 0.10 23.82 ± 2.29 24.78 ± 1.48
YWHAZ 29.25 ± 0.68 26.72 ± 0.28 29.47 ± 2.05 31.06 ± 0.85Page 6 of 11
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(Table 4). Using NormFinder in clinical samples we
observed that the most stable candidates were the follow-
ing:
PPIA>POLR2A>18S>HMBS>RPLPO>IPO8>ACTB>YWH
AZ, with stability values < 0.4 (Table 4). Genes with stabil-
ity values between 0.4 and 0.6 were HPRT1, TBP, PGK1,
UBC, GUSB, and TFRC. The worse stable genes were
GAPDH and B2M.
Consequently, the best three genes using GeNorm were
IPO8, ACTB, and POLR2A, whereas the best three candi-
dates using NormFinder were PPIA, POLR2A, and 18S. We
conclude from both analyses that IPO8, ACTB, POLR2A,
18S and PPIA are suitable reference genes for lung biop-
sies. Furthermore, these genes exhibited a high Pearson
correlation among themselves (r = 0.981–0.857) (supple-
mental Text S2 and Supplemental Table 6, Additional file
1). Moreover, IPO8 was the gene with the highest number
of significant correlations (supplemental Table 7, Addi-
tional file 1). Since we had two different top-ranked can-
didates, depending on the type of analysis, we carried out
further experiments to identify the best normalizing gene
among the best five genes.
This analysis was performed using the Set C sample, and
calculating the means ± SEM of |ΔCt| (|Ct Normal-Ct
Tumor|) for the aforementioned five genes (Figure 3). The
Table 3: Candidate reference genes for normalization of qRT-PCR (in lung cultured cells) ranked according to their expression 
stability by GeNorm and NormFinder programs
GeNorm NormFinder
Genes Stability value Genes Stability value
PPIA 0.377 Most stable genes PPIA 0.078
RPLPO 0.377 RPLP0 0.199
GAPDH 0.387 HPRT1 0.232
18S 0.430 GAPDH 0.244
HPRT1 0.473 18S 0.257
GUSB 0.509 GUSB 0.328
POLR2A 0.547 POLR2A 0.407
HMBS 0.580 UBC 0.408
PGK1 0.614 PGK1 0.420
UBC 0.644 HMBS 0.425
ACTB 0.681 ACTB 0.508
B2M 0.719 B2M 0.529
TFRC 0.761 TFRC 0.583
YWHAZ 0.801 YWHAZ 0.631
IPO8 0.852 IPO8 0.758
TBP 0.917 Least stable genes TBP 0.863
Table 4: Rank of expression stability (in lung tissues) calculated by GeNorm and NormFinder softwares
GeNorm NormFinder
Genes Stability value Genes Stability value
IPO8 0.245 Most stable genes PPIA 0.253
ACTB 0.245 POLR2A 0.267
POLR2A 0.344 18S 0.276
18S 0.466 HMBS 0.318
PPIA 0.530 RPLP0 0.323
HMBS 0.564 IPO8 0.336
RPLP0 0.599 ACTB 0.360
YWHAZ 0.658 YWHAZ 0.383
PGK1 0.717 HPRT1 0.430
HPRT1 0.774 TBP 0.474
TBP 0.823 PGK1 0.484
GAPDH 0.872 UBC 0.510
UBC 0.931 GUSB 0.535
B2M 0.984 TFRC 0.586
GUSB 1.045 GAPDH 0.653
TFRC 1.101 Least stable genes B2M 0.701Page 7 of 11
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follows: 18S(0.563 ± 0.123)>IPO8(0.638 ±
0.222)>ACTB(0.875 ± 0.153)>POLR2A(0.878 ±
0.242)>PPIA(1.633 ± 0.201). The tests of paired data
showed no significant differences between normal and
malignant tissues for IPO8 (p = 0.877), whereas signifi-
cant differences were found for all the other genes: PPIA
(p = 0.000), 18S (p = 0.007), POLR2A (p = 0.011) and
ACTB (p = 0.046). Therefore, IPO8 can be considered the
best candidate, taking into account all these criteria (high
stability, low mean ± SEM of |ΔCt| with no significant dif-
ferences between paired samples, and number of correla-
tions).
IPO8 as the most accurate reference gene for 
clinicopathological specimens
In order to further validate IPO8 as the best control gene
for lung tissues, a third analysis was performed in Sets
A+C samples. In addition, we used this analysis to reex-
amine PPIA as a putative control gene (since it was top-
classified by NormFinder) and to further validate the inac-
curacy of GAPDH and HPRT1 as normalizing genes for
clinicopathological lung specimens. In this case, we used
|ΔCt| ± SEM, but not expression stability based on
GeNorm and NormFinder, because the validity of this latter
analysis relies on examining a large number of genes (typ-
ically 5 to 10) [16].
The test of paired data revealed no significant differences
between normal and malignant samples for IPO8 mRNA
levels (|ΔCt| = 0.70 ± 0.09). On the contrary, the three
other genes showed significantly different |ΔCt| values
when comparing non-malignant with malignant tissues
(Figure 4). IPO8 was also the gene with the lowest SEM
(Figure 4). Therefore, these results confirmed that IPO8 is
the best reference gene for normalizing lung tissue sam-
ples. PPIA showed |ΔCt| = 1.45 ± 0.17, and GAPDH and
HPRT1 had the highest difference in |ΔCt| (on average)
between normal and tumor samples: 2.42 ± 0.20 for
GAPDH and 1.91 ± 0.21 for HPRT1.
Discussion
The identification of novel diagnostic tools and therapeu-
tic targets for lung cancer relies on the accurate normaliza-
Average of absolute values of ΔCt of IPO8, ACTB, POLR2A, 18S and PPIAFigure 3
Average of absolute values of ΔCt of IPO8, ACTB, POLR2A, 18S and PPIA. Mean ± SEM of |ΔCt| (=|Ct Normal-Ct 
Tumor|) of five selected optimally performing reference genes (IPO8, ACTB, POLR2A, 18S and PPIA) in paired lung clinical 
samples (Set C).Page 8 of 11
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constant in both normal and malignant tissues. Stringent
requirements for selecting endogenous controls are essen-
tial, and the task of identifying normalization genes is not
trivial. Several recent papers have demonstrated that clas-
sical "housekeeping" genes such as GAPDH, HPRT1, and
ACTB (β-actin) are inaccurate to normalize different types
of clinical samples [23,25-27] In the present study, we
have analyzed the expression of a panel of 16 genes in
lung cancer cell lines and biopsies, with the goal of iden-
tifying the most accurate candidate to be used as a refer-
ence gene. The main finding of our study is the
identification of importin-8 (IPO8) as a very robust refer-
ence gene for lung clinical specimens, which could
become the gold-standard endogenous gene for lung tis-
sues.
One first conclusion is that GAPDH and HPRT1, the two
most commonly reference genes used in the literature, are
not suitable for the normalization of gene expression lung
biopsies. Nonetheless, our data also show that the use of
both genes is perfectly appropriate for expression studies
using lung cell lines. In contrast, in clinical specimens we
have clearly shown a significant increase in GAPDH and
HPRT1 mRNA levels in tumors (as compared to normal
matched tissues) and low expression stability. Despite
GAPDH was widely used in the past, its use as a reference
gene has recently been challenged in the majority of
tumor types, including melanoma [22], liver [23], bladder
[24], renal cancer [25], prostate [26], gastroesophagic and
pancreatic cancer [27], and colon adenocarcinoma [28].
In vitro assays have demonstrated that GAPDH contrib-
utes to diverse cellular functions related to glycolysis,
nuclear RNA export, DNA replication and repair, exocyto-
sis, and cytoskeletal organization [29]. GAPDH was also
suggested to play a role in the pathogenesis of cancer [29].
Remarkably, antisense oligodeoxynucleotides targeting
GAPDH inhibit cell proliferation and induce apoptosis in
cervical carcinoma cells. Taken together our results and
data from the literature, in spite of a previous study pro-
posing GAPDH as a good normalizing gene for lung biop-
sies [21], we strongly suggest not to use this gene for gene
expression normalizing purposes in lung.
IPO8 as the most accurate reference gene in lung specimensFigure 4
IPO8 as the most accurate reference gene in lung specimens. Average (mean ± SEM) of |ΔCt| of the two commonly 
used reference genes (GAPDH and HPRT1), PPIA and the novel reference gene IPO8 in paired lung clinical samples (Sets 
A+C).Page 9 of 11
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BMC Molecular Biology 2008, 9:103 http://www.biomedcentral.com/1471-2199/9/103In our search for the most accurate gene to normalize lung
specimens, we ranked the 16 candidate genes according to
expression stability, and mean of |ΔCt| ± SEM values.
According to GeNorm, the best three genes in terms of
expression stability were IPO8, ACTB, and POLR2A,
whereas using NormFinder PPIA, POLR2A, and 18S were
top-classified. From both analyses, we consequently pro-
posed a set of five genes (IPO8, ACTB, POLR2A, 18S and
PPIA) as suitable reference genes for lung specimens. Con-
sidering the lowest |ΔCt|, 18S was top-ranked (0.563 ±
0.123), closely followed by IPO8 (0.638 ± 0.222). How-
ever, statistical comparison of expression levels between
normal and malignant tissues found no differences exclu-
sively for IPO8, but not for any other gene. In addition,
expression of IPO8 strongly correlated (r2 > 0.9) with that
of 18S, ACTB, and POLR2A. IPO8 had also the highest
number of gene correlations. In view of all these results we
conclude that IPO8 is the most robust reference gene for
lung cancer studies. Indeed, we further validated the accu-
racy of IPO8 as a reference gene in a different set of sam-
ples and found again that Ct values for normal samples
were statistically similar to those of tumors.
Interestingly, IPO8 has never been proposed as a potential
reference gene in cancer research. Importin 8 (IPO8), a
gene located at 12p11.21, which encodes a protein of
1037 aminoacids, is a member of a class of approximately
20 potential Ran targets that share a sequence motif
related to the Ran-binding site of importin-beta. This pro-
tein binds to the nuclear pore complex and, along with
RanGTP and RANBP1, inhibits the GAP stimulation of the
Ran GTPase. The importin-alpha/beta complex and the
GTPase Ran mediate nuclear import of proteins with a
classical nuclear localization signal [30].
Despite its accuracy in the normalization of lung clinical
samples, IPO8 is not the best option for in vitro studies.
Although |ΔCt| for IPO8 was also very low in cell lines, its
expression is not stable (according to Genorm and
NormFinder analysis). In cell lines, PPIA was top-classified
in terms of expression stability, followed by RPLPO, 18S,
and HPRT1. 18S was included in the group of optimally
performing endogenous genes in all the analyses of our
study, for both cell lines and clinical samples. Therefore,
18S could be an alternative to IPO8 when a study required
the use of cell lines and biopsies with a single reference
gene. However, 18S rRNA levels are extremely high (Ct
values between 12.6–12.8) in comparison to other target
housekeeping mRNAs, which may increase the risk of
introducing quantification errors. In addition, some stud-
ies have suggested that mRNA transcripts should not be
normalized with a ribosomal RNA, because of their unre-
lated expression mechanisms [31].
Systematic comparisons of gene sets in different types of
tumors have recently led to the selection of a variety of
optimal reference genes: SDHA and TBP for bladder [24],
18S for gastric and colorectal [27], PPIA and TBP for renal
[25], HPRT1 for prostate [26], SFRS4 for hepatocellular
carcinoma [23], or B2M for colon adenocarcinoma [28].
It seems clear that a single definitive universal reference
gene has not been identified yet, and may be very difficult
to find, as tissue specific gene expression is the basis for
tissue and organ differentiation. Consequently, appropri-
ate control genes for each specific tumor type need to be
selected among a variety of candidates, using stringent
mathematical criteria.
Conclusion
We can draw several important conclusions from our
study: a) GAPDH and HPRT1 are not suitable genes to
normalize lung specimens but are appropriate when using
lung cell lines; b) The best performing reference genes for
lung cell lines are not coincident with those of clinical
samples; c) PPIA is a novel reference gene for lung cell
lines; d) Finally, and most importantly, we have described
for the first time that Importin-8 is the best performing
gene to normalize clinicopathological lung samples and
should be considered as the main option when using lung
biopsies. We believe that this finding will help further
studies to normalize potential new targets for diagnosis
and treatment of lung cancer.
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